The terms of the placement are for the purchase of common shares at $1.60 per share and include one warrant per share at an exercise price of $2.24 and have an expiry of five years from the date of issue.
"We expect that these funds will allow us to complete the Phase I component of the Polish trial and all the preparatory work required for the previously approved US Phase I clinical trial of L-DOS47 in combination with Pemetrexed and Carboplatin", stated Robert Verhagen, President & CEO of Helix.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with this private placement.